Potential barriers in lipid-lowering treatment with PCSK9 inhibitors from a healthsystem perspective. Comparative evidence from ten countries.

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Efstratios Apostolou

LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail

Simulated intervention and optimal timing for attenuating dyslipidaemia-related atherosclerotic progression in the young: a temporal inverse allocation analysis of the ALSPAC cohort

Doctor A. Agbaje (Kuopio, FI)

Abstract Slides

Presentation thumbnail

Elevated levels of Lp(a) are associated with coronary lesion complexity in patients hospitalized for an acute myocardial infarction: data from the French RICO Survey

Doctor M. Kouame (Abidjan, CI)

Abstract Slides

Presentation thumbnail

Association of propionate with coronary artery disease in a large cross-sectional study

Professor N. Pagonas (Neuruppin, DE)

Abstract Slides

Presentation thumbnail

Evaluation of the effects of immunization against PCSK9 on selected microRNAs involved in cholesterol homeostasis.

Professor M. Banach (Lodz, PL)

Abstract Slides

Presentation thumbnail

Realistic approach to evaluate the effect of baseline lipid profile in post cardiac surgery: Restricted Cubic Spline model

Doctor A. Sheikhy (Tehran, IR)

Abstract Slides

Access the full session

Session thumbnail

Lipids 2

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

Lipidomics to fine-tune cardiovascular risk prediction and personalised treatment

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources